Kornimate/medical-research-clean huggingface dataset:
pediatric chronic rhinosinusitis in asthmatic children

Conditions: Sinusitis in Children

Summary: the objectives of this study would be to determine the most effective treatment for children with pcrs and asthma who fail medical management.

this prospective, randomized study would involve children age 6-12 with symptoms of both pcrs and asthma. their symptoms would first be managed medically with standard medical therapy. in the event they fail medical management, patients would then be randomized to two treatment arms, either adenoidectomy alone or adenoidectomy with ess. ct scan of the sinuses would then be obtained to evaluate the extent of sinus disease and aid in preoperative planning in those patients undergoing ess. sinus mucosa thickening seen on ct is also integral in the diagnosis of pcrs, according to consensus statements published by the american academy of otolaryngology. at each visit patient's symptoms would be measured with the sn-5, a validated questionnaire for tracking pcrs.

Eligibility criteria:
inclusion criteria: * inclusion criteria: age 6-12 at time of study enrollment. presence of chronic sinusitis: \>90 days 2 or more symptoms of purulent rhinorrhea, nasal obstruction, facial pressure/pain, or cough with corresponding endoscopic and/or ct findings in a patient 18 years or younger. presence of asthma, as documented in the medical record by the patient's pediatrician and/or pulmonologist exclusion criteria: * exclusion criteria include previous sinus surgery, previous adenoidectomy, or presence of cystic fibrosis, antrochoanal polyp, immunodeficiency, or fungal infection.
neoadjuvant temozolomide combined with simultaneous imrt for treatment of glioblastoma

Conditions: Glioblastoma

Summary: this study is a prospective, multi-center, randomized controlled clinical study. indications: glioblastoma diagnosed after surgery (who grade iv). the patient received conventional postoperative concurrent radiotherapy and chemotherapy, or neoadjuvant temozolomide combined with concurrent increased intensity-modulated radiotherapy. according to data from previous clinical trials, conventional doses of concurrent radiotherapy and chemotherapy pfs 6.9 months neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy pfs 13.7 months, an estimated 20% leakage rate, and a total sample size of 80 patients.


Eligibility criteria:
inclusion criteria: * age: 18 to 70 years old * a patient with high-grade (who grade iv) glioma diagnosed pathologically * ecog score ≤ 3 points * the expected survival time is greater than 3 months * patients undergoing surgery for the first time * patients who have not received radiotherapy at the treatment site in the past * the following hematological indicators need to be met neutrophil count ≥1.5×109/l hemoglobin ≥9g/dl platelet count ≥70×109/l * the following biochemical indicators need to be met total bilirubin≤1.5×upper limit of normal (uln) ast and alt\<1.5×uln creatinine clearance rate ≥60ml/min * patients of childbearing age need to take appropriate protective measures (contraception or other methods of birth control) before enrollment and during the trial * the signed informed consent form * ability to follow research protocols and follow-up procedures exclusion criteria: * patients with recurrent glioma who have previously undergone surgery or radiotherapy and chemotherapy * glioma of the spinal cord * ecog score\> 3 points * severe mental symptoms; uncontrollable status epilepticus * patients with malignant tumors in other parts * the patient has an active bacterial, viral or fungal infection (≥ grade 2 nci-ctc, 4th edition) * the patient has severe liver and kidney dysfunction, hiv infection, hcv infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that the researcher thinks cannot be included in the group * pregnant and lactating women. women of childbearing age must have a negative pregnancy test within 7 days before joining the group * drug abuse, clinical, psychological or social factors affect informed consent or research implementation * any uncertain factors that affect the safety or compliance of patients
clinical and prognostic comparisons between invasive pulmonary aspergillosis with or without invasive tracheobronchitis during severe influenza: a retrospective multicenter cohort study.

Conditions: Invasive Pulmonary Aspergillosis; Morality

Summary: invasive tracheobronchial aspergillosis (itba) is an uncommon, but severe clinical form of invasive pulmonary aspergillosis (ipa) in which the fungal infection is entirely or predominantly confined to the tracheobronchial tree. in view of the limited data concerning critically ill patients admitted to the intensive care unit (icu) with severe influenza associated with itba, the investigators decided to evaluate the differences between the clinical presentations of two invasive infections: itba and ipa without tracheobronchial involvement (no itba).

invasive pulmonary aspergillosis (ipa) is a well-known complication in severely immunocompromised hosts patients. recent evidence has identified others populations at risk for ipa, including those with chronic obstructive pulmonary disease (copd) and advanced cirrhosis patients in intensive care units (icus). moreover, recently influenza has been identified as a new independent risk factor for ipa and ipa was described as an early complication of influenza. ipa groups different clinical presentations: the classical angio-invasive, the broncho-invasive form and the invasive tracheobronchitis aspergillosis form (itba). itba is an infrequent clinical form of ipa with often a fatal outcome, in which aspergillus infection involves entirely or predominantly the tracheobronchial tree. early diagnosis of itba is based on bronchoscopy examination. severe influenza is a life-threatening condition where ipa has been repeatedly reported. little is known on severe influenza infection complicated with ipa and still less with itba. current data on itba in critically ill patients hospitalized for severe influenza infection has only been described in single case reports. because itba has been associated with a poorer prognostic than other forms of ipa, this retrospective study aimed to analyze diagnostic and prognostic differences between itba and ipa without tracheobronchial lesions, in critically ill patients with influenza infection hospitalized in icu.

Eligibility criteria:
inclusion criteria: * all icu (intensive care unit) patients * patients aged from 18 years and more * all patients hospitalized in icu with a positive influenza rt-pcr extracted from the registry of the local virology department * patients with a diagnosis of influenza confirmed by a positive influenza real time polymerase chain reaction (rt-pcr) from nasopharyngeal swab or bronchoalveolar lavage (bal) fluid, with a concomitant diagnosis of proven or probable/putative ipa and the performing of a bronchoscopy exclusion criteria: * minor or adult with guardianship * absence of hospitalization in intensive care * influenza infection not confirmed by pcr

Keywords: invasive pulmonary aspergillosis invasive tracheobronchial aspergillosis galactomannan 1,3-β-d-glucan influenza intensive care unit mortality
tolerance and pharmacokinetics of shr1459 in patients with recurrent replased/refractory mature b cell neoplasmstumor

Conditions: Mature B Cell Neoplasms

Summary: shr1459 is a selective small molecule btk inhibitor developed by jiangsu hengrui medicine limited, by inhibiting the phosphorylation of btk and down regulation of bcr signal transduction pathway, and then selectively inhibit the proliferation and migration of b cell tumor.

shr1459 is a selective small molecule btk inhibitor developed by jiangsu hengrui medicine limited, by inhibiting the phosphorylation of btk and down regulation of bcr signal transduction pathway, and then selectively inhibit the proliferation and migration of b cell tumor. the objective of this phase 1 study is to evaluate the safety and tolerance of shr1459 in patients with replaced/refractory mature b cell neoplasms, in order to determine the maximum tolerated dose (mtd) and recommended dose for phase 2 clinical study (rp2d);

Eligibility criteria:
inclusion criteria: * ecog performance status \[ps\] score must be 0 or 1; * life expectancy ≥ 12 weeks; * mature b cell eoplasmss with histological or cytological diagnosis, including diffuse large b cell lymphoma (dlbcl), follicular lymphoma (fl) , chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl) and waldenstrom macroglobulinemia (wm); * the function of bone marrow is basically normal; * renal function is basically normal; * hepatic function is basically normal. exclusion criteria: * had received treatment with the compound of the same mechanism (btk inhibitor); * with infiltration of lymphoma central nervous system; * received autologous stem cell transplantation within 60 days before signing the informed consent, received allogeneic stem cell transplantation in 90 days (after allogeneic stem cell transplantation, if graft-versus-host disease appeared, it must be ≤ level 1, and if there was no prohibited medication, the screening could be performed);

Keywords: replased/refractory mature b cell neoplasms btk inhibitor
docetaxel (taxotere), vinorelbine, and bevacizumab, as adjuvant chemotherapy for patients with resected stage i-iii non-small cell lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to determine whether a combination of the drugs docetaxel (taxotere ® ), plus vinorelbine (navelbine ® ), will result in fewer side effects than cisplatin chemotherapy, thereby improving delivery of chemotherapy in patients. another purpose of this study is to determine whether a third drug, bevacizumab (avastin®), may be delivered safely with docetaxel plus vinorelbine in patients who are eligible to receive bevacizumab.


Eligibility criteria:
inclusion criteria: * patients must be at least 2 weeks status post complete (r0) surgical resection of pathologically-proven nsclc (stage ia-iiib). pathology review will be performed independently at mskcc. * patients are eligible if they are unfit for cisplatin-based adjuvant chemotherapy based on specified clinical criteria (listed below). * allergy to cisplatin * baseline hearing loss (defined as any subjective baseline hearing deficit, even if it does not require a hearing aid or intervention, or interfere with activities of daily life (ctcae grade \> or equal to 2) * baseline renal insufficiency (defined as a creatinine clearance of \< than or equal to 60 ml/min as calculated by the equation of cockcroft and gault using the patient's age, weight (kg), and serum creatinine (mg/dl). * performance status 70% on the karnofsky scale. * congestive heart failure with new york heart association functional classification \> or equal to ii, characterized by fatigue, dyspnea or other symptoms which limit activities of daily life. * patient refuses to take cisplatin. * age \> than or equal 18 * performance status karnofsky \> than or equal to 70% * peripheral neuropathy must be \< than grade 1 * hematologic (minimal values) * absolute neutrophil count \> than or equal to 1,500/mm3 * hemoglobin \> than or equal to 8.0 g/dl * platelet count \> than or equal to 100,000/mm3 hepatic * total bilirubin \< than or equal to 1.5 x uln ast or alt and alkaline phosphatase must be within the range allowing for eligibility * women of childbearing potential must have a negative pregnancy test. * men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. * patients being considered for treatment with bevacizumab must have a urine protein: creatinine (upc) ratio \< 1.0 at screening and an mri of brain or ct brain with iv contrast showing no evidence of brain metastases within 3 months of study entry exclusion criteria: * \> 16 weeks post-op * prior post-operative radiation * \> 1 cycle of prior adjuvant chemotherapy * patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. * women who are pregnant, or breast-feeding.

Keywords: bevacizumab (avastin) taxotere (docetaxel) vinorelbine tartrate (navelbine) 07-178
ibrutinib with rituximab in adults with waldenström's macroglobulinemia

Conditions: Waldenström's Macroglobulinemia

Summary: the purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with waldenström's macroglobulinemia (wm).


Eligibility criteria:
eligibility criteria for the randomized study inclusion criteria: * untreated or previously treated for wm. previously treated subjects must have either documented disease progression or had no response (stable disease) to the most recent treatment regimen * centrally confirmed clinicopathological diagnosis of wm * measurable disease defined as serum monoclonal immunoglobulin m (igm) \>0.5 g/dl * symptomatic disease meeting at least 1 of the recommendations from the second international workshop on waldenström macroglobulinemia for requiring treatment * hematology and biochemical values within protocol-defined limits * men and women ≥ 18 years of age * eastern cooperative oncology group (ecog) performance status of ≤ 2 exclusion criteria: * known involvement of the central nervous system by wm * disease that is refractory to the last prior rituximab-containing therapy defined as either * relapse after the last rituximab-containing therapy \< 12 months since last dose of rituximab, or * failure to achieve at least a minor response (mr) after the last rituximab-containing therapy if the subject meets this exclusion criterion and therefore is excluded from the main randomized study, participation in the non randomized substudy (arm c) may be considered * rituximab treatment within the last 12 months before the first dose of study drug * known anaphylaxis or (immunoglobulin e) ige-mediated hypersensitivity to murine proteins or to any component of rituximab * prior exposure to ibrutinib or other bruton's tyrosine kinase (btk) inhibitors * known bleeding disorders (eg, von willebrand's disease) or hemophilia * history of stroke or intracranial hemorrhage within 12 months prior to enrollment. * any uncontrolled active systemic infection. * any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk. * currently active, clinically significant cardiovascular disease * requires treatment with a strong cytochrome p450 (cyp) 3a inhibitor eligibility criteria for open-label substudy treatment arm c the inclusion/exclusion criteria for the substudy (arm c) are identical to those described above for the randomized study but, to be eligible, subjects need to be considered refractory to the last prior rituximab-containing therapy defined as either * relapse after the last rituximab-containing therapy \<12 months since last dose of rituximab, or * failure to achieve at least a mr after the last rituximab-containing therapy.

Keywords: ibrutinib pharmacyclics pcyc lymphoma btk inhibitor wm rituximab rituxan waldenström's waldenstrom macroglobulinemia non-hodgkin lymphoma nhl
learning modality in individuals with diabetes incompatible

Conditions: Diabetes Mellitus, Type 2

Summary: this study was planned to examine the effect of education based on learning styles in diabetic individuals who are incompatible with treatment, on treatment compliance and metabolic goals. the study was conducted as a randomized controlled study between january-september 2021 in dokuz eylül university training and research hospital endocrinology and metabolic diseases polyclinic and internal medicine polyclinic.

among the individuals who applied to the outpatient clinic and were eligible for inclusion in the study, the odd numbers were assigned to the application group, and the even numbers to the control group. the practice group of 30 people and the control group were divided into 3 groups as auditory (n: 10), visual (n: 10) and physical learners (n: 10). research data; the individual identification form was collected using the patient compliance scale for type 2 dm treatment, the big 16 learning styles inventory, the standardized mini mental test (smmt) and the metabolic goal control form. the training group was given according to the learning styles. the auditory group in the post-training practice group; calling by phone, to the visual group; by sms, to the physical group; reminder alerts were made by phone + sms. standard training was given to the control group. metabolic target values of the application and control groups were examined at 3 and 6 months after the training.

Eligibility criteria:
inclusion criteria: 1. age range of 20-65, 2. at least 6 months diagnosis, 3. ability to communicate in turkish, 4. mentally stable, with no vision, verbal, or hearing impairments 5. not having any obstacle to continue the implementation phase of the research (for example, pregnancy plan, change of city, etc.), 6. not having advanced hearing-vision problems and another serious disease or serious complication due to diabetes (amputation, etc.) 7. it is to get a score between 55 and 150 (incompatible with treatment) from the patient compliance scale in type 2 dm treatment. exclusion criteria: \*he/she received training on recurrent diabetes at dokuz eylul university hospital. to be, * the patient's perception disorder and psychiatric disorder that prevent communication to be found, * having been diagnosed with cancer, * being pregnant, * blind retinopathy, advanced neuropathy and foot wound

Keywords: diabetes education learning style compliance with treatment metabolic target
flail chest: a randomized controlled study

Conditions: Flail Chest

Summary: flail chest refers to a section of the rib cage that has broken away from the surrounding ribs. usually, more than one rib is involved, and they are broken in at least two places. flail chest typically is the result of blunt chest trauma. as a result of flail chest, the chest wall becomes unstable and dangers of life threatening respiratory failure and hypoxemia (lack of oxygen to circulating blood which will lead to organ damage or failure)occur. currently, these injuries are treated non operatively. however, small case series have demonstrated that operative management can improve intensive care unit (icu) length of stay, improved pulmonary function and decreased pain leading to decreased duration of mechanical ventilation, and the incidence of complications related to this injury. this study hopes to provide information on whether a prospective randomized trial is feasible by first undertaking a small pilot study to determine rate of recruitment, data collection methods, and integrity of study protocol. null hypothesis 1: enrollment of subjects with flail chest rib fractures into a prospective multi-centre rct is not feasible and a larger clinical trial is unlikely to be completed.

the optimum treatment of flail chest rib fractures is currently unknown. the standard of care for these injuries at most centers in north america, includes a progressive algorithm of epidural anesthesia, mechanical ventilation, and tracheostomy. surgical management of flail chest injuries has previously been reserved for refractory cases unable to wean from mechanical ventilation or severe chest wall instability. however, the use of surgical stabilization of multiple rib fractures has demonstrated substantial improvements in icu length of stay, duration of mechanical ventilation, and the incidences of pneumonia, tracheotomy, and reintubation. these results have been reported in small cases series without prospective or randomized trial designs.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years old * greater than or equal to 4 adjacent rib fractures, with greater than one fracture per rib * provide informed consent exclusion criteria: * does not meet inclusion criteria * attending physician does not believe the subject will survive their injuries

Keywords: flail chest
pulsed electromagnetic field (pemf) therapy in thumb cmc arthritis

Conditions: Thumb Osteoarthritis

Summary: long-term objective: determine if high-frequency pemf therapy reduces pain in patients with thumb carpometacarpal (cmc) joint osteoarthritis (oa). study design and methods: this will be a randomized controlled pilot study with 60 subjects with cmc oa randomly divided in two groups. thirty subjects will receive high-frequency pemf therapy overlying the cmc joint overnight daily for four weeks. the other 30 subjects will receive a sham pemf therapy device applied to the same joint overnight daily for four weeks. pain and function questionnaires will be obtained for all patients at enrollment, four weeks, and six weeks.


Eligibility criteria:
inclusion criteria: * an existing diagnosis of cmc oa by a hand specialist based on clinically (tenderness to palpation at the cmc joint and/or positive cmc grind test) and/or radiographically identified cmc oa * reported pain intensity during activities of daily living less than 7 on the numeric pain rating scale (nprs) exclusion criteria: * pregnant * unable to consent * with current infection in hand or upper extremity * have had prior fracture, significant hand injury, tenosynovitis, complex regional pain syndrome, and/or dupuytren's disease affecting the thumb * history of surgical or procedural intervention for cmc oa in the hand of study interest * do not speak english * have hand or wrist implants * have heart or brain implants